Impact of Immunohistochemistry Subtypes on Survival Outcomes in Breast Cancer with Spinal Metastases: A Comprehensive Review and Meta-Analysis - Takeaways - MDSpire

Impact of Immunohistochemistry Subtypes on Survival Outcomes in Breast Cancer with Spinal Metastases: A Comprehensive Review and Meta-Analysis

  • By

  • Fon-Yih Tsuang

  • Yun-Heng Li

  • Ting-Li Shen

  • Chiun-Sheng Huang

  • Chung Liang Chai

  • February 21, 2026

  • 0 min

Share

  • 1

    Breast cancer is classified into three immunohistochemistry-based subtypes: HR +, HER2 +, and triple-negative breast cancer (TNBC), each with distinct prognostic implications.

  • 2

    HR + breast cancer shows the highest median survival (26.4 months), while TNBC has the poorest survival rates (6.0 months) among the subtypes.

  • 3

    Breast cancer is the most common primary tumor in surgically treated spinal metastases, accounting for 18.5% of cases in a global cohort.

  • 4

    Current literature on survival outcomes for breast cancer with spinal metastases is limited, necessitating comprehensive pooled survival data for better clinical decision-making.

  • 5

    This systematic review aims to fill the knowledge gap by providing pooled survival data for breast cancer subtypes, enhancing therapeutic guidance for affected patients.

Original Source(s)

Impact of Immunohistochemistry Subtypes on Survival Outcomes in Breast Cancer with Spinal Metastases: A Comprehensive Review and Meta-Analysis

  • by Fon-Yih Tsuang, Yun-Heng Li, Ting-Li Shen, Chiun-Sheng Huang, Chung Liang Chai

  • February 21, 2026

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation